Biologies targeting TNF-a and IL-6 have dramatically changed the treatment of rheumatoid arthritis (RA). Previously the therapeutic aim was to control the symptoms of arthritis. However, today our treatment goal is to achieve remission. Inflammatory cytokines involved in the pathology of RA activate multiple signaling pathways in the cytoplasm. Hence, regulating these intracellular signaling pathways has been expected to achieve similar treatment effects as biologies on RA. Recent clinical trials with compounds targeting Janus kinase (JAK) or spleen tyrosine kinase (Syk) have demonstrated high clinical efficacy resembling the biologies. Here we overview the development process of these inhibitors together with the results of clinical trials.
|ジャーナル||Japanese Journal of Clinical Pharmacology and Therapeutics|
|出版ステータス||Published - 2013 1 1|
ASJC Scopus subject areas